Compare Abeona Therapeutics Inc (ABEO) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Hilton Hotels Corporation Common Stock trades at $333.13 (market cap $77.66B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 208× Abeona Therapeutics Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HLT | |
|---|---|---|
Market Cap | $373.32M | $77.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $350.22 |
52-Week Low | $4.17 | $256.75 |
Enterprise Value | $228.22M | $90.15B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Hilton Worldwide (HLT) trades at $341.12, up 0.89% with strong technical momentum as price approaches resistance at $342. The stock shows consistent earnings beats with Q1 2026 EPS of $2.01 exceeding expectations of $1.98, while revenue growth continues from $12.04B in 2025 to projected $12.3B in 2026. Analyst consensus remains bullish with 55% buy ratings and a $342.11 price target closely aligned with current levels.
The outlook remains positive given Hilton's market leadership and sustained travel demand, though elevated debt levels and valuation multiples present risks. With technical indicators showing bullish momentum and strong institutional support, the stock appears positioned for continued growth, though investors should monitor debt management and competitive pressures in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
